long engag near end
doj approv ci-esrx deal septemb us depart
justic doj approv acquisit express script two
compani still need approv total requir state
brief chat compani note continu expect close
deal end
pro-forma ep estim reiter year one accret
target mid-teen ep accret target time
deal announc mid-teen accret impli ep accret
pro-forma ep ex-antm contract pro-
forma ep estim primarili driven higher baselin
ci ep estim year one ep accret remain unchang
pro-forma ep estim
respect keep stand-alone ep estim
chang pt methodolog rais pt doj approv
valu ci share pro-forma ci-esrx estim ci share
current trade pro-forma ep estim versu group
averag roughli see share trade discount
mco given compani busi mix expect discount
narrow least next twelv month would impli ci
share trade pro-forma ep estim yield
pt repres upsid roughli current
level risk rate pt includ state approv take longer
expect esrx deal integr risk unexpect pick-up medic
util trend unexpect pressur core esrx
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
headquart bloomfield ct global health servic
health global supplement benefit group disabl
life
blue sky valuat asum pro-forma ci-esrx
trade pro-forma ep estim
grey sky valuat assum pro-forma ci-esrx
face oper challeng core busi esrx
pbm busi scenario see ci share trade
pro-forma ep estim
price sep rate outperform target price analyst rice
profit tax
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
total debt capit
 close
compani mention price
